What's Happening?
The drug discovery process faces significant challenges due to the limitations of current preclinical models, which often fail to accurately replicate human physiology. This discrepancy leads to high attrition rates in clinical trials, with approximately
90-95% of drug candidates failing during development. The reliance on animal models and immortalized cell lines has proven inadequate for predicting human responses, particularly for complex diseases like Alzheimer's and Parkinson's. To address this, researchers are advocating for the use of human induced pluripotent stem cell (iPSC)-derived models, which offer a more accurate representation of human biology. These models can improve the predictive validity of preclinical research, potentially reducing development costs and timelines.
Why It's Important?
The high failure rate in drug development not only delays the availability of new therapies but also incurs substantial financial losses. By integrating human-centric models early in the discovery pipeline, the pharmaceutical industry can enhance the accuracy of preclinical testing, leading to more successful clinical outcomes. This shift could streamline the drug development process, making it more efficient and cost-effective. Additionally, the use of human cell models aligns with ethical considerations by reducing reliance on animal testing. As the industry moves towards more collaborative and data-driven approaches, standardizing human cell models will be crucial for generating reliable data and improving the overall success rate of drug discovery.
